Login to Your Account

Repligen Tanks After FDA Cancels AdComm on RG1068

By Marie Powers
Staff Writer

Friday, April 27, 2012
Repligen Corp. delivered another disappointment Thursday, disclosing that the FDA canceled the advisory committee meeting scheduled for May 31 to review pancreatic imaging candidate RG1068. The company expects to receive a complete response letter requesting additional clinical data to support its new drug application (NDA) for RG1068, which has a PDUFA date of June 21.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription